Transgene S.a annual current ratio
2020
2021
2022
2023
2024
2025
Transgene S.a Current Ratio Growth & History (TNG)
Transgene S.a's current ratio was 9.62 for fiscal 2025.
View full Transgene S.a company overviewTransgene S.a annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 9.62 | 8.14 | +550.92% |
| 2024 | 2024-12-31 | 1.48 | −0.31 | −17.47% |
| 2023 | 2023-12-31 | 1.79 | −1.85 | −50.78% |
| 2022 | 2022-12-31 | 3.64 | −0.63 | −14.72% |
| 2021 | 2021-12-31 | 4.27 | 2.01 | +89.49% |
| 2020 | 2020-12-31 | 2.25 | — | — |
Transgene S.a quarterly current ratio
Q4.24
Q4.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 9.62 | 8.14 | +550.92% |
| Q4 2024 | 2024-12-31 | 1.48 | — | — |
Transgene S.a current ratio trends
Over the last five fiscal years, Transgene S.a's current ratio increased from 2.25 to 9.62, a change of 7.37. The latest reported quarter, Q4 2025, shows 9.62.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as reported current assets divided by reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transgene S.a source filings ↗Community posts
Transgene reports €92.8 million in liquidity as vaccine development advances
Transgene ($TNG) reported €92.8 million in cash, cash equivalents and other current financial assets at its half-year end, compared with €111.9 million at the start of the year. First-half cash burn increased to €20.3 million from €18.8 mil ...
